Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Tislelizumab + Capecitabine in Perioperative HER2+ Gastric Cancer
NCT06560528Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Sep 2024
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in gastric cancer (GC), gastroesophageal junction adenocarcinoma, sponsored by Tianjin Medical University Cancer Institute and Hospital. Started Sep 2024; status: recruiting.
02
Drugs
disitamab vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06560528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06560528.